Find and follow us on LinkedIn:

Welcome
to Pharmora

Pharmora provides assured global medical review services for the clinical development and safety surveillance of medical products, from the first clinical trials to ongoing commercialisation.

We have a highly capable team of medics and scientists available to provide flexible and dedicated assured services, at your convenience.

Please visit our About us page

Click here to hear from Pharmora Limited’s Stephanie Jones and Ian Pinches as they discuss the benefits of attending the World Drug Safety Congress 2024 and what they do at Pharmora Limited

Our Mission: Quality without compromise

Pharmora is a preferred strategic partner for the following services:

Clinical Development

Pharmora can provide medical and scientist expertise to support your clinical development projects at all phases and through regulatory submission to approval. Click here for Clinical Development case studies.

Patient Safety

Pharmora was built on a foundation of safety expertise throughout the product life cycle. Click here for safety case studies.

Medical & Regulatory Writing

Pharmora can work seamlessly with your team to evaluate the data and ensure the documents accurately convey your key messages.

Training and more

Pharmora runs training courses on key skills and can provide bespoke training packages depending on your needs.

Where are you in your product life cycle?

Pre-clinical

Early clinical development

Phase II-III clinical
development

NDA / MAA submission

Life cycle
management

Pre-clinical

Early clinical development

Phase II-III clinical development

NDA / MAA submission

Life cycle
management

'Splendid Turn-Around'

‘“Two Pharmora Medical Scientists slotted seamlessly into the clinical team, already trained on a complicated protocol for a phase III registrational oncology trial in patients with resectable lung cancer. They were able, from the first day, to get straight on with patient profile reviews for an important database lock of event free survival. Within 2 months, they had helped turn-around a precarious, uncertain situation to allow us to meet our planned timelines. A splendid execution from two of Pharmora’s Medical Scientists, who are now sought after by another study team within our organisation.’

Clinical Development Scientist
Senior Director

'100% reliable'

“I have worked with Stephanie {Pharmora’s CMO} for 15 years in pharmacovigilance, at the start of her PV career at Abbott and since then Stephanie and I have worked on multiple projects and pieces of work as a consultant.

She is 100% reliable and delivers items on time to the required quality. In addition Stephanie has a great ability to reach people across many cultures and languages. In terms of pharmacovigilance process areas Stephanie has all bases covered in her wide experience across local, regional and global process areas.

At a personal level I wouldn’t hesitate to commission additional work from Steph or collaborate on a project with her.”

Andrew Cooper,
Baxalta Associate Director Pharmacovigilance Asia / ANZ

'Critical Support When Needed'

‘I had the pleasure of working with a Pharmora Medical Scientist who joined the team at a critical moment when the study’s database lock and submission activities were imminent. His onboarding was swift and efficient. In his early weeks, he had significant contribution to DBL finalization and despite his very short presence in the study he was able to replace more experienced team members in data cleaning activities with very good understanding and quality. He has always been very eager in taking on new responsibilities, grasping every possibility to learn new skills and took over several study activities in time. Every task assigned he completed in a timely manner and with quality exceeding expectations. He was very soon able to work independently but remaining in good contact with the team.’

Global Medical Scientist Director, Clinical Development

Top Five Pharmaceutical Company

Our latest thinking

Understanding Gaucher Disease

Gaucher disease is a rare genetic disorder caused by a deficiency in the enzyme glucocerebrosidase, leading to a harmful buildup of fat in cells. This causes symptoms like enlarged organs, bone pain, and, in some cases, neurological impairment. Current treatments offer relief but come with limitations such as inconvenient infusions, side effects, and the inability to address neurological symptoms. Read on to discover the promising new developments bringing hope for this rare disease…

The MHRA’s Patient Involvement Strategy 2021-25

The MHRA launched the Patient Involvement Strategy 2021-2025. Now, in the final year of the strategy, what has been done for Patient Involvement, and what do the MHRA plan to do next? Read on to learn…

The EMA’s IRIS platform – what is it, and what does it mean for MAHs?

The EMA is transitioning all of the communications during the Marketing Authorisation process to its IRIS platform, read on to learn more about what this might mean for you.

Find and follow us on LinkedIn:

Welcome
to Pharmora